Compare ANDE & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANDE | ANAB |
|---|---|---|
| Founded | 1947 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | 2017 |
| Metric | ANDE | ANAB |
|---|---|---|
| Price | $59.50 | $47.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $58.33 | ★ $60.18 |
| AVG Volume (30 Days) | 259.3K | ★ 489.7K |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.13 | N/A |
| Revenue | ★ $11,595,817,000.00 | $169,467,000.00 |
| Revenue This Year | $6.45 | $135.51 |
| Revenue Next Year | $3.37 | N/A |
| P/E Ratio | $28.27 | ★ N/A |
| Revenue Growth | 2.19 | ★ 196.42 |
| 52 Week Low | $31.03 | $12.21 |
| 52 Week High | $62.10 | $52.47 |
| Indicator | ANDE | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 64.61 | 54.75 |
| Support Level | $56.96 | $44.25 |
| Resistance Level | $62.10 | $48.53 |
| Average True Range (ATR) | 1.68 | 2.96 |
| MACD | 0.46 | -0.20 |
| Stochastic Oscillator | 74.61 | 66.35 |
Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).